CAR-T cells + vaccines

CAR-T cell therapy combined with vaccines represents an innovative combination immunotherapy approach designed to enhance the efficacy of CAR-T cells, particularly for solid tumors. This combination therapy leverages vaccines to boost CAR-T cell expansion, persistence, and therapeutic efficacy in vivo[4].\n\nThe combination works through complementary mechanisms: CAR-T cells provide a tumor-targeting immune infiltrate that can recognize and attack cancer cells in an MHC-independent manner, while vaccines help to extend CAR-T cell persistence, prevent exhaustion, and enhance their killing function[5]. Various vaccine types have been studied in this combination, including dendritic cell (DC) vaccines, mRNA vaccines, and peptide-derived vaccines[5][6].\n\nClinical trials have shown promising results for this combination approach, particularly in addressing limitations of CAR-T cell therapy alone, such as poor persistence, rapid exhaustion, and limited efficacy against solid tumors[4][5][6].

Brand names

BNT211BNT-211BNT 211